📊 Interpreting the ESSDAI
| ESSDAI | Activity Level | Clinical Meaning |
|---|
| < 5 | Low Activity | Well-controlled or clinically stable. Monitor at regular intervals. |
| 5 to 13 | Moderate Activity | Standard trial inclusion threshold. Consider systemic treatment intensification. |
| ≥ 14 | High Activity | Significant organ involvement. Systemic immunosuppression warranted. |
MCID: a decrease of 3 or more points defines treatment response in clinical trials. Maximum theoretical ESSDAI is 123, though scores above 20 are uncommon.
💡 Pearls and Pitfalls
✓
ESSDAI and ESSPRI measure different dimensions with low correlation. ESSDAI captures physician-assessed systemic organ activity. ESSPRI captures the patient's subjective symptom burden. Correlations between them are only r = 0.07 to 0.29. Always use both instruments together for a complete assessment.
✓
Attribution is the hardest part. Only score features attributable to active primary Sjogren's. This requires clinical judgment. The muscular domain (weight 6) and the respiratory domain (weight 5) have the greatest potential impact and require the most careful attribution to active disease versus prior damage or comorbidity.
⚠
ClinESSDAI excludes the biological domain. Many newer trials use ClinESSDAI (which excludes domain 12) to avoid confounding by B-cell biomarkers when using B-cell-targeting therapies. ClinESSDAI = this ESSDAI score minus the weighted biological domain contribution.
🔬 Evidence
ESSDAI was developed by the EULAR Sjogren's Task Force (Seror et al., Ann Rheum Dis 2010), using data from 96 patients to generate 702 clinical vignettes rated by 39 international experts. Validation across 15 countries (n=395) confirmed good construct validity, responsiveness, and reliability. Disease activity thresholds and the MCID were established by Seror et al. in Ann Rheum Dis 2016 using anchor-based methods in two large prospective cohorts (total n=790).
View References▾
1
Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69(6):1103-9.
2
Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859-66.
3
Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with ESSDAI and ESSPRI. Ann Rheum Dis. 2016;75(2):382-9.
4
Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren's syndrome patient-reported index (ESSPRI): development of a consensus patient index. Ann Rheum Dis. 2011;70(6):968-972.